ONCOFERTILITY & SEXUAL HEALTH IN MEN: A SURVIVORSHIP GUIDE BEFORE, DURING, AND AFTER TREATMENT

Introduction

Cancer treatments can be life-saving for male patients but often come with significant side effects on reproductive and sexual health. Many male cancer patients—especially adolescents and young adults—identify future fertility and sexual function as top concerns when facing a cancer diagnosis. In fact, roughly half of young male patients express a desire to have children in the future, and sexual health is a major component of their quality of life post-treatment.

Unfortunately, cancer therapies such as chemotherapy, radiation, surgery, and hormone treatments can impair spermatogenesis (sperm production), disrupt hormones, and damage nerves or blood vessels involved in sexual function. These effects may be temporary in some cases, but they can also be long-lasting or permanent in others, leading to infertility or sexual dysfunction for survivors.

Despite the prevalence of these issues, discussions about fertility and sexual side effects are not always routine in oncology care. Surveys indicate that up to 87% of cancer survivors experience changes in sexual function or desire after treatment, yet fewer than 30% were formally asked about these issues by their health care team. Only about 40% recall being warned before treatment that their sexual health might be affected. This communication gap can leave patients unprepared and distressed. Men often report feeling that loss of fertility or erectile function impacts their sense of masculinity and overall happiness. Unaddressed, these concerns can lead to depression, relationship strain, and regret over missed opportunities for fertility preservation. It is therefore crucial for healthcare providers to proactively address reproductive and sexual health at each stage of the cancer journey.

Modern guidelines emphasize a proactive, multidisciplinary approach. The American Society of Clinical Oncology (ASCO) and other expert bodies recommend that all patients of reproductive age be informed of potential fertility risks as early as possible, ideally at diagnosis. Patients interested in future fertility should be promptly referred to a reproductive specialist before treatment begins. Similarly, sexual health should be acknowledged as an integral part of survivorship care. A patient-friendly yet academically rigorous approach—combining medical options and complementary therapies—can help men navigate these sensitive issues. This article will review the fertility and sexual concerns of men undergoing cancer treatment at three key stages: before treatment (at diagnosis), during treatment, and after treatment, and discuss how these concerns can be addressed at each stage. We will examine the emotional and physical challenges men face, the influence of partners, family, and friends, and both conventional and complementary strategies for preserving fertility and sexual function.

Before Treatment: Addressing Concerns at Diagnosis

Fertility Preservation Discussions and Options

When a man is newly diagnosed with cancer, there is often a small window before treatment begins to address fertility preservation. At this stage, the primary concern is usually whether future fertility will be possible and what can be done to safeguard it. Men commonly ask questions such as, “Will I be able to have children after this treatment?” and “Should I bank sperm before starting therapy?” These are critical questions to address upfront. Clinical practice guidelines strongly encourage physicians to discuss the risk of infertility with patients at the time of diagnosis, prior to initiating cancer therapy. By informing patients early, those who wish to preserve fertility can take action before any gonadotoxic (harmful to the reproductive cells) treatment is given.

Sperm cryopreservation (sperm banking) is the gold-standard fertility preservation method for post-pubertal males. This involves collecting a semen sample (usually through masturbation) and freezing it for future use. Sperm banking is highly effective and widely available in most developed countries. The ASCO guidelines state that sperm cryopreservation should be offered to all pubertal and post-pubertal males before cancer-directed treatment begins (1). Even if the patient is unsure about wanting children, banking is recommended because it preserves the option – it is essentially an “insurance policy” for future fertility. The process is quick (often a sample can be obtained within a day or two) and does not significantly delay cancer treatment in most cases. If a patient is unable to produce a sample due to stress or illness, techniques like testicular sperm extraction (TESE) can sometimes retrieve sperm directly from testicular tissue surgically (2). TESE may also be considered if a man’s semen sample has no sperm (azoospermia) at baseline, which can occur with certain cancers (for example, some men with testicular cancer have low or zero sperm counts even before treatment). For adolescent boys who are not yet producing sperm (prepubertal patients), experimental options like testicular tissue cryopreservation are being studied – this involves freezing a small piece of testis in the hope of generating sperm later. However, this is considered investigational and typically only available in research protocols at this time. Counseling families about such experimental techniques requires careful discussion of uncertainties.

It’s important to set realistic expectations during these discussions. Cancer treatments vary in their impact on fertility. Alkylating chemotherapy drugs (like cyclophosphamide or platinum agents), as well as radiation to the testes or brain (pituitary gland), are known to carry a high risk of long-term or permanent infertility in men. Other treatments may pose a lower risk. For example, some men may recover sperm production a few years after therapy if the treatment was less gonadotoxic or if they were younger and had a higher baseline sperm reserve. Because it is difficult to predict an individual’s recovery, the default approach is “bank before treatment, just in case.” Studies show that even among men who are undecided about future children, those who bank sperm tend to have less regret later than those who do not. In one study, cancer survivors who had received fertility counseling and the opportunity to bank had significantly lower long-term regret compared to those who were not counseled. Therefore, specialists should strongly encourage sperm banking unless a patient explicitly refuses or in rare cases where it’s absolutely impossible.

One barrier to sperm banking at diagnosis can be the urgency of starting cancer treatment. Patients with very aggressive cancers might need to begin therapy within days, leaving little time for banking. Even then, arrangements can often be made to collect at least one sample in the short time available. For example, a patient can often produce a sample the same day or next day after diagnosis if needed. Most chemotherapy can be safely held for 24–48 hours for this purpose without impacting cancer outcomes, although this should be decided on a case-by-case basis. If immediate surgery is planned (such as removal of a testicular tumor), sperm banking before surgery is ideal, because surgery (like orchiectomy for testicular cancer) might remove or impair a sperm source. In some cases that require emergency treatment (e.g., acute leukemia needing urgent chemotherapy), a quick sperm banking attempt is still recommended if the patient is able. Coordination between oncology and fertility teams is key – many centers have oncofertility programs or referral networks to expedite preservation in these scenarios. The presence of a dedicated oncofertility specialist (often a reproductive urologist or fertility doctor) greatly facilitates this process.

It’s worth noting that historically, sperm banking was underutilized. Older studies from the 2000s found that only about 24–31% of eligible young men banked sperm before treatment when it was offered. Reasons for declining included being unsure about wanting children, already having children, or misconceptions (for instance, some men felt banking wasn’t needed if they had a vasectomy or if their partner had tubal ligation, or they believed treatment wouldn’t affect fertility). There were also logistical and psychological barriers—some men felt too overwhelmed by the cancer diagnosis to focus on fertility, or were uncomfortable with the process of producing a sample on short notice. However, with increasing awareness, utilization has improved. In the United States, many cancer centers now include automatic referrals for fertility preservation. One academic center reported that before establishing a formal oncofertility program, only 3.3% of male cancer patients at that hospital underwent sperm banking, but after the program and education were in place, this rose to 19.3% (a six-fold increase) (3). This demonstrates how proactive counseling and streamlined referrals can dramatically increase uptake. Most men, when properly informed, do opt to preserve their fertility if possible. Indeed, a recent survey of survivors found 97% felt that having the possibility to protect their fertility was very important at the time of diagnosis. Even men who already had children sometimes bank sperm, in case they want more later. Specialists should ensure that lack of information or support is never the reason a patient misses the opportunity to preserve fertility. If cost is a concern (since fertility preservation may not always be covered by insurance), patients should be informed of any financial assistance programs or sperm bank payment plans; many regions have initiatives or charities to help subsidize fertility preservation for cancer patients.

Sexual Health and Function at Baseline

Before treatment, men may also worry about how cancer and upcoming therapy will affect their sexual function. At diagnosis, the cancer itself can sometimes impact hormones or anatomy. For instance, testicular cancer can cause low testosterone levels or reduced sperm production even before any treatment, which might lead to symptoms like decreased libido or subfertility at baseline. Similarly, a man diagnosed with prostate cancer might already experience erectile dysfunction (ED) or urinary symptoms due to the tumor’s effects. However, many newly diagnosed patients, especially young men, have normal sexual function at that time – which makes the prospect of losing it due to treatment particularly daunting. The anxiety and emotional stress of a cancer diagnosis alone can transiently affect a man’s ability to have erections or interest in sex. It’s not uncommon for men to feel “nervous and not in the mood” when facing a serious diagnosis, or to experience situational ED from stress.

Open discussion and baseline assessment of sexual function should be part of the pre-treatment consultation. This can be as simple as the doctor or provider asking, “Are you currently sexually active, and do you have any issues with erections or libido that we should know about?” It’s important to normalize the conversation, as many patients won’t bring it up on their own. In fact, male patients often appreciate when clinicians proactively mention fertility and sexual side effects, as it signals that these are legitimate medical concerns, not “taboo” topics. Unfortunately, not all providers are comfortable with this; one survey found that female patients were rarely asked about sexual health, and while male patients were asked more often, still only about half reported their doctor ever inquired about it. For medical professionals, especially those not well-versed in male reproductive health, initiating such conversations can be challenging. Yet, doing so is part of holistic cancer care. If a provider feels uncertain, this is an ideal time to involve a specialist such as a urologist, sexual medicine expert, or even a certified sex therapist to help assess and counsel the patient.

From a practical standpoint, documenting baseline fertility and sexual function is useful. Some specialists will obtain a semen analysis before treatment, not only to assess sperm count for banking purposes but also to have a point of reference for recovery after treatment. Baseline hormone levels (like testosterone, follicle-stimulating hormone [FSH], and luteinizing hormone [LH]) can also be checked. For example, if a man already has low testosterone or high FSH (indicating testicular dysfunction) before therapy, he might be at even higher risk for infertility or sexual side effects from treatment – this could further support the urgency of sperm banking or planning for testosterone replacement after treatment if needed. However, routine hormone testing isn’t mandatory if it wouldn’t change management prior to treatment; it can be deferred to survivorship follow-up.

Prehabilitation for sexual function can be considered in some cases. For instance, in prostate cancer patients who plan to undergo prostatectomy (surgical removal of the prostate), a specialist might discuss nerve-sparing surgical techniques with the surgeon to maximize postoperative erectile function. They might also advise starting penile rehabilitation soon after surgery (using medications or devices to promote blood flow to the penis and prevent disuse atrophy – more on that in the post-treatment section). In men with testicular cancer, if one testis will be removed, the patient should be counseled that the remaining testis often compensates in testosterone production and sperm output, but not always – hence monitoring and possible testosterone therapy later might be needed if symptoms of low testosterone occur. At the pre-treatment stage, knowing that plans are in place to manage these issues can be reassuring to the patient.

Emotional and Psychosocial Support at Diagnosis

Being told you have cancer is an emotionally overwhelming experience. On top of grappling with mortality and starting treatment, young men in particular may feel a profound sense of loss at the prospect of infertility or sexual changes. Negative emotions such as fear, anxiety, and even shame are common. Some men feel that a cancer affecting their reproductive organs (like testis, prostate) is “embarrassing” or strikes at their manhood. They may worry that “not being able to have children is no different from being disabled,” or that erectile dysfunction would make them feel less masculine. These sentiments were captured in a qualitative study of testicular cancer patients, where one man said: “I was ashamed of my inability to get an erection and infertility.”. Such feelings can lead to isolation – for example, some patients hide their diagnosis from friends or avoid dating because they are unsure how a partner might react to their condition and potential infertility.

At this stage, involving partners and family in discussions can be very beneficial. If the patient has a spouse or significant other, that person is likely also anxious about the future, and they should be part of the fertility planning conversation whenever possible. Partners can provide emotional support and help the patient remember information. Moreover, the partner’s family-building desires are directly relevant – decisions about sperm banking often involve considering the partner’s wishes for children as well. Many partners are very supportive of fertility preservation; for instance, they might encourage the patient to bank sperm so that together they have the possibility of a family after cancer. In some cases, if time allows, couples may even pursue creating embryos (via in vitro fertilization) before cancer treatment, which is another form of fertility preservation (this is more common if the patient’s female partner is also of reproductive age and they are ready to create embryos). However, creating embryos is a more involved process and not usually feasible unless treatment can be safely delayed for a few weeks (which is rare in male cancers, but sometimes considered in certain scenarios). Sperm banking is much simpler and faster, so it remains the primary recommendation.

Family members (like parents of a young adult patient) can also influence decisions. Parents often play a big role when the patient is an adolescent or young adult. Some parents actively push for fertility preservation – wanting to ensure their son has a chance at future children (and that they might have future grandchildren). Others might be so focused on “curing the cancer” that they downplay fertility, inadvertently discouraging the patient from worrying about it. Healthcare providers should be mindful of these dynamics. Ideally, a counselor or social worker with experience in oncofertility can be involved to help families navigate these sensitive topics. In some cultures, talking about masturbation or sexual matters with parents present can be uncomfortable. The medical team might arrange some private time with the patient to discuss sperm banking instructions if needed. Written and online resources can supplement verbal counseling, giving the patient something to refer to later.

Importantly, patients should be reassured that feeling conflicted or upset is normal, and that resources are available. Many men feel they must “be strong” and not show emotion, but they may be internally distressed by potential loss of fertility or sexual function. A specialist well-versed in male reproductive health will acknowledge these feelings. For example, they might say, “I know this is a lot to deal with – worrying about survival and also about your future ability to have kids or be intimate. These concerns are completely valid. We have counselors and support groups for young cancer patients that can help you cope with these issues.” Indeed, connecting newly diagnosed patients with peer support (such as other survivors who went through similar struggles) can alleviate feelings of isolation. Some organizations (like fertility preservation networks or cancer survivor groups) have peer mentoring programs. Hearing success stories – for instance, a survivor who banked sperm and later had a healthy child, or someone who had erectile issues but recovered with treatment – can provide hope.

Partner influence at this stage can be both positive and negative. On the positive side, a loving partner can reassure the patient that “we’ll face this together” and that their relationship is not solely contingent on sexual function or fertility. Some men worry their partner will leave them if they can’t have children or have sexual difficulties. Open communication can counter these fears. On the other hand, if a relationship is new or uncertain, the patient might worry about burdening the partner. A few patients may even avoid dating or put off marriage plans because of fears about fertility. For example, young men in one study voiced concern about “not knowing how and when to tell future partners” about their fertility status, worried that a partner might not “accept this” and that it could lead to breakups. These are valid concerns that should be addressed with compassionate counseling. Often, a mental health professional (psychologist or psychiatrist) who specializes in cancer or sexuality can help patients develop communication strategies for disclosing and discussing these topics with current or future partners.

In summary, before treatment begins, the focus is on education and proactive measures: banking sperm, documenting baseline status, optimizing upcoming treatments to be as fertility- and nerve-sparing as possible, and providing emotional support. This stage sets the foundation for a patient’s hope – knowing that steps were taken to preserve fertility can be a great psychological relief as they enter treatment. As one survivor reflected, even though he wasn’t sure if he would use his frozen sperm, “having the possibility of protecting my fertility was very important”. The peace of mind that one aspect of the future is safeguarded allows the patient to focus more confidently on the fight against cancer.

During Treatment: Managing Fertility and Sexuality Through Therapy

Once cancer therapy is underway – whether it’s chemotherapy, radiation, surgery, or a combination – men encounter new challenges. This period can last months or even years (for example, some treatments like endocrine therapy in prostate cancer are long-term). During treatment, the body is under physical stress, and side effects can directly impact reproductive function and sexual health. The key concerns for men at this stage often include: “Are my treatments causing permanent damage to my fertility?”; “What can I do (if anything) right now to reduce harm to my sperm or sexual function?”; “Is it safe to be sexually active during treatment, and how do I deal with a lack of desire or performance issues?” Addressing these questions requires a coordinated care approach, often involving oncologists, urologists, endocrinologists, and psychosocial support providers.

Impact of Treatment on Fertility (and Mitigation Strategies)

Different cancer treatments have varying effects on male fertility. Chemotherapy, especially regimens including alkylating agents (like cyclophosphamide, ifosfamide, platinum drugs such as cisplatin) or high cumulative doses, tend to be the most gonadotoxic. Within 1–2 months of starting chemo, sperm count and motility typically decline. Many men become azoospermic (no sperm in ejaculate) after a few cycles, particularly with high-dose regimens. The good news is that in some cases this is temporary – spermatogenesis can recover gradually over 1–3 years after treatment, depending on drug type and dose. However, with certain drugs (e.g. platinum-based chemotherapy as used in testicular cancer), studies have reported persistent ED and fertility issues in a significant subset of patients. One study noted that among men treated for testicular cancer with platinum chemo, about 40% reported erectile dysfunction, and many had prolonged low sperm counts. Drugs like cyclophosphamide can kill spermatogonia (the stem cells for sperm) and lead to permanent infertility at high doses. Radiation therapy to areas near the testes (such as pelvic radiation for prostate, bladder, or rectal cancer) can also impair sperm production by scatter or direct exposure. Even relatively low doses of radiation (as low as 1 Gy) can suppress spermatogenesis, and direct testicular radiation above ~4 Gy can cause permanent azoospermia. Radiation to the brain (pituitary) can lower the signals (FSH/LH) that drive sperm production, also affecting fertility indirectly. Surgery can impact fertility if it involves removal of reproductive organs (e.g., bilateral orchiectomy removes sperm source entirely; prostatectomy removes the prostate and seminal vesicles, causing loss of semen and often retrograde ejaculation or no ejaculation). Hormonal therapies (like androgen deprivation therapy for prostate cancer) profoundly suppress sperm production and sexual function during the treatment period, though these effects are intended to be reversible after stopping therapy (testosterone and sperm production usually resume, but it can take time and is not guaranteed in older men).

Given these assaults on fertility, what can be done during treatment? If a patient banked sperm beforehand, the emphasis during treatment is on preventing any unintended pregnancy and protecting the partner – because sperm produced during therapy may carry genetic damage from chemotherapy. Men are usually advised to avoid conceiving during active treatment and for a period after (often 6-12 months post-treatment). This is to ensure any sperm used for conception are not damaged by chemotherapy or radiation. For example, ASCO guidelines note that sperm collected shortly after therapy may have higher rates of DNA damage, and patients should be counseled about this risk. Therefore, effective contraception (condoms or having the partner on birth control) is important if the patient is sexually active with a partner who could become pregnant. If a man did not bank sperm before and is now in the middle of treatment, the options are limited. Cryopreservation during treatment is generally not recommended, because by the time most men consider it, their sperm count may already be very low or zero due to the ongoing chemo/radiation, and any sperm obtained might have DNA damage. There are rare cases where a patient who initially refused or couldn’t bank before will attempt to bank after a couple of chemo cycles if they miraculously still have sperm. However, they must be informed that the success may be low and there could be genetic risks. Some centers test such samples for DNA fragmentation, but it’s not routine. Overall, the ship of fertility preservation has largely sailed once chemotherapy has started, underscoring the importance of pre-treatment counseling.

One question that arises is whether there are medical interventions during treatment to protect fertility. In women, ovarian suppression with GnRH agonists has been used as an ovarian-protective strategy during chemo (with mixed success, primarily in breast cancer patients). In men, attempts to use hormonal suppression (like GnRH agonists or testosterone to shut down the testis temporarily) have been mostly experimental. Animal studies suggested that putting the testicles “at rest” might make them less susceptible to chemo damage, but clinical evidence in humans is lacking. No proven medication exists to shield the testis in the way some drugs (e.g., amifostine) can protect other organs. Antioxidants and supplements (discussed further below) are sometimes tried, but there’s no consensus or guideline-recommended pharmacologic protective agent for male fertility during treatment. For example, GnRH analogs in men are not recommended purely for fertility protection (and they would cause temporary chemical castration, which could actually worsen quality of life by eliminating testosterone during an already difficult time). Thus, the focus remains on mechanical protection: in radiation therapy, techniques like testicular shielding or aiming radiation fields away from gonads as much as possible are employed to reduce scatter dose. If a man is getting pelvic radiation, the radiation oncologist might position him and use blocks to spare the testes. For certain surgeries (like retroperitoneal lymph node dissection for testicular cancer), nerve-sparing techniques can preserve ejaculatory function to avoid retrograde ejaculation, which helps maintain natural fertility potential if sperm production continues.

During treatment, the role of the fertility specialist shifts more to monitoring and planning for the future rather than active intervention. They might periodically check hormone levels or semen analyses if appropriate (though often patients are too ill to bother with semen tests during chemo). If the patient is on a long-term treatment (e.g., 3 years of androgen deprivation for prostate cancer), a specialist may discuss ways to manage the hypogonadism symptoms, but actual fertility attempts will wait until therapy is done.

Sexual Function Challenges During Treatment

Sexual side effects can manifest quickly once treatment starts. Fatigue, nausea, pain, and the general malaise of chemotherapy can greatly diminish libido (sex drive). It’s hard to feel sexual while dealing with intense treatment side effects. Many men temporarily lose interest in sex during active chemo simply because they feel unwell. Body image changes can also play a role: hair loss, surgical scars, or weight changes might affect a man’s self-esteem and comfort with intimacy. For example, after a testicular surgery, a young man might feel self-conscious about having one testicle. While a testicular prosthesis (implant) can be placed to restore the appearance of two testicles, this is often done at the time of surgery or can be done later; discussing it beforehand is important for those concerned about appearance. In the same qualitative study mentioned earlier, some men kept their diagnosis secret due to feelings of shame and altered masculinity, illustrating how powerful these body image issues can be.

Erectile dysfunction (ED) is a major concern during certain treatments. For instance, men undergoing radical prostatectomy often experience immediate ED post-surgery due to nerve damage – erection quality may improve over 6–24 months if nerves were spared, but during that period, assistance is needed (more on interventions later). Men receiving pelvic radiation may notice a more gradual onset of ED, often months after treatment, as radiation can cause fibrosis of blood vessels and nerves that affect erections. In one large study of prostate cancer patients, 2 years after treatment about 79% of those who had surgery and 61% of those who had radiation reported ED; by 5 years, the numbers were around 75% and 72% respectively. So essentially, most men had significant ED during the initial survivorship period regardless of modality, though radiation’s effects sometimes appeared a bit later than surgery’s. Chemotherapy itself can cause ED in some men, indirectly through fatigue, neuropathy, or vascular damage. As noted, ~40% of men on platinum chemo for testicular cancer reported ED by standardized questionnaires. Another study found that about 1 in 4 testicular cancer survivors had some degree of ED, and 10% had severe ED. Part of this can be due to low testosterone from losing one testis or from chemo’s effect on Leydig cells (the testosterone-producing cells), as well as psychological stress. Hormonal therapy (ADT) for prostate cancer virtually guarantees loss of libido and ED during treatment, since it eliminates testosterone (the hormone that drives sexual desire and erections). Men on ADT often experience hot flashes, fatigue, muscle loss, and mood changes, compounding sexual issues.

Communication and counseling during treatment are vital. Patients and their partners should be informed about these potential side effects up front, so that they are not taken by surprise. For example, a man starting radiation to the pelvis should know that his erections might worsen over the next year – this helps set expectations and encourages early action (like using erectile aids proactively). A simple but important piece of advice is: remaining sexually active if possible, or at least having regular erections (even if through masturbation or with aid of medication), can help preserve erectile tissue health. Some data suggest that “use it or lose it” applies to erectile function: penile tissues need oxygenation from erections. If a man goes many months with no erections at all (like after prostate surgery), the penile smooth muscle can undergo fibrosis, making later recovery more difficult. Thus, specialists often encourage some form of penile rehabilitation during and after treatment. This might include low-dose nightly PDE5 inhibitors (like sildenafil) to promote blood flow, or use of a vacuum erection device (VED) to mechanically induce an erection a few times a week to keep the tissues healthy. The patient should understand that these measures are not necessarily to have intercourse immediately, but to improve long-term function.

However, not all men can or want to engage in sexual activity during therapy, and that’s okay. The priority is treating the cancer. But men should know that if sexual side effects arise, there are interventions. Medications for ED, such as PDE5 inhibitor pills (Viagra[sildenafil], Cialis[tadalafil], etc.), can be used during treatment unless contraindicated (for example, if the patient’s health allows sexual activity – some men with cardiac issues or extreme fatigue might not be ready). These medications require some level of remaining erectile function to work. In cases like post-prostatectomy, where nerves are recovering, these drugs may have limited effect initially. Alternatively, intracavernosal injections(self-injection of a drug like alprostadil into the penis) can produce erections mechanically and may be an option even during treatment if a patient is highly motivated to maintain sexual activity. In practice, though, many men put active sex on hold during intensive chemo or radiation and revisit treatments for ED afterward. Testosterone replacement is generally not used during cancer treatment (with rare exceptions) because if the cancer is hormone-sensitive (like prostate cancer, or certain male breast cancers), testosterone is contraindicated. Even in others, doctors often wait until cancer is in remission before addressing low testosterone, since high testosterone might theoretically feed any hormone-sensitive tumor or is simply not prioritized. That said, if a patient on treatment (not hormone-sensitive) has severely low testosterone levels and debilitating symptoms, an endocrinologist or urologist might carefully consider supplementation on a case-by-case basis, but this is uncommon during active cancer therapy.

Maintaining intimacy in non-physical ways can be important for couples during treatment. Patients should be reminded that closeness and sexual satisfaction need not always equal intercourse. Kissing, touching, and communication of needs are crucial. If intercourse is difficult or not possible for a time, couples can explore other ways of intimacy. Some couples benefit from sex therapy or counseling to adapt their sexual life to the “new normal” during treatment. Involving the partner in discussions, as appropriate, ensures that they understand it’s the treatment causing these changes, not a lack of interest. Partners sometimes misinterpret a patient’s fatigue or ED as lack of attraction or emotional distance, so clear communication is key: “I love you, but the chemo is making me too tired,” or “This medication is affecting my ability, but I still desire closeness.”

Safety of sexual activity during treatment is another aspect to cover. Men often wonder if it’s safe to have sex while on chemotherapy. The primary concern is that small amounts of chemotherapy drugs can be present in semen, so there’s a theoretical risk to the partner (like causing irritation or exposure). The amounts are likely minimal, but as a precaution, many oncologists advise using condoms during intercourse on the days immediately following chemo administration (usually the first 48–72 hours) to avoid exposing the partner to any drug in bodily fluids. Also, if platelet counts are very low, vigorous sex might risk bleeding; if white counts are low, there’s infection risk. So common-sense adjustments (gentler activity, good hygiene, barrier protection) are wise if immunity is compromised. If the patient has radiation implants (brachytherapy) for prostate cancer, there are sometimes specific instructions to avoid close contact for a period – but with modern low-dose brachytherapy seeds, the radiation exposure to a partner is negligible, still some are advised to use condoms initially to catch any extruded seeds (rare occurrence). These specifics should be explained by the treating team.

Emotional Well-Being and Support Networks During Treatment

The middle of cancer treatment is often likened to “being in the trenches” – the initial shock has passed, but now the day-to-day reality of therapy sets in. Emotional health can take a downturn due to the physical toll and the uncertainty of outcomes. Depression and anxiety are common during this phase, and these can further dampen sexual interest and strain relationships. Men might feel a loss of control over their life and body. Fertility and sexual function issues can exacerbate this feeling. For example, a man who was hoping to have a child after treatment might become increasingly anxious as he experiences side effects that imply infertility (like lack of ejaculation after surgery or prolonged azoospermia after chemo).

Partner and family support remain crucial. Partners often transition into a caregiver role during treatment – driving the patient to appointments, helping with daily tasks when the patient is fatigued, etc. This shift can alter the couple’s dynamic. While many partners are steadfast and supportive, the change in roles can sometimes reduce the romanticaspect temporarily. For instance, a patient may say, “I don’t feel like her husband right now, I feel like a patient,” and the partner might feel similarly that they’ve become more of a nurse than a lover. Acknowledging this dynamic and finding small ways to maintain normalcy can help (such as a movie night or gentle physical affection that reminds both of their bond beyond illness). In some cases, counseling for the couple (couples therapy) can provide a safe space to discuss these feelings. Healthcare providers should watch for signs of relationship strain. Social workers and psycho-oncologists can assist if a partner is excessively anxious or if communication issues arise.

Friends and extended family also influence the patient’s coping. Supportive friends can boost morale, whereas insensitive comments can hurt. Sadly, young men with cancer might get well-meaning but misguided remarks from peers like “at least you don’t have to worry about getting anyone pregnant now, ha ha,” which trivialize their fertility loss. Educating the patient’s support network (with the patient’s permission) that fertility and sexual function are important aspects of survivorship can foster more empathy. Some patients choose to share their fertility preservation efforts with close friends or family, which can lead to a helpful discussion instead of awkward silence. Others prefer privacy, which should be respected.

Professional emotional support is highly recommended during treatment. Depression not only affects quality of life but can also reduce treatment adherence. If a patient is very distressed by sexual or fertility issues, a mental health professional can teach coping strategies. Techniques from cognitive-behavioral therapy (CBT) can help challenge catastrophic thoughts (e.g., “No one will ever want me if I’m infertile” or “I’m less of a man now”) and reframe them more positively. Mind-body interventions are also valuable at this stage. Practices such as mindfulness meditation, relaxation exercises, or guided imagery have been shown to reduce stress in cancer patients and even improve sexual health indirectly by reducing performance anxiety. For example, mindfulness techniques encourage individuals to stay present and engaged in sensual experiences without focusing solely on performance (erections or orgasm), which can be especially beneficial for men experiencing ED due to anxiety. There is preliminary evidence that mindfulness-based sex therapy can increase sexual satisfaction in prostate cancer survivors by shifting the focus away from erections and toward intimacy and pleasurable sensations. Men undergoing treatment could start learning these techniques (often via audio apps or with a therapist’s guidance). Even simple deep-breathing or progressive muscle relaxation can help manage the stress that might otherwise dampen libido or erection quality.

Complementary therapies can also play a role in symptom management during treatment, which in turn can support sexual health. For example, acupuncture has been studied in cancer patients primarily for symptom control (like chemotherapy-induced nausea, pain, or fatigue). Some studies in breast cancer patients found acupuncture helped with therapy-related symptoms (hot flashes, fatigue) and improved overall quality of life and sex drive compared to pharmaceutical interventionsWhile the evidence in male cancer patients is not as robust, some men use acupuncture to help with neuropathy (nerve pain) from chemo or pelvic pain after surgery. By alleviating pain and improving energy, acupuncture might indirectly help a man feel more capable of sexual activity. It is considered safe when done by a licensed practitioner and can be integrated as part of supportive care. Herbal supplements and dietary adjustments are sometimes sought out by patients during treatment, but these should be used with caution. Some men ask about supplements purported to boost fertility or protect the testicles (such as certain antioxidants). For instance, lab research in animal models has shown that natural compounds like curcumin (from turmeric) and ellagic acid (from pomegranates) can mitigate chemo-induced damage to the testes. In rats, curcumin co-administered with cisplatin chemotherapy helped preserve normal testicular cell architecture and reduced markers of oxidative DNA damage in sperm cells. Similarly, ellagic acid has been noted to ameliorate cisplatin’s toxicity on the male reproductive system, improving sperm parameters and organ weights in animal studies. Vitamin C and other antioxidants have also demonstrated protective effects in preclinical studies, restoring sperm count and motility in rodents exposed to certain toxic drugs. However, it is crucial to stress that these findings are from animal or laboratory studies. Clinical trials in human cancer patients are lacking or inconclusive. Moreover, high-dose antioxidants taken during chemotherapy could theoretically interfere with treatment efficacy (by protecting not only normal cells but also cancer cells from oxidative damage). Oncologists often advise against excessive supplementation during therapy for this reason. Therefore, any complementary supplement should be discussed with the medical team. A balanced diet rich in natural antioxidants (fruits and vegetables) is generally encouraged, but popping high-dose supplement pills is usually discouraged unless part of a study or known to be safe.

In summary, during treatment, the strategy is twofold: (1) manage and mitigate side effects – use available medical interventions to address ED, loss of libido, and other sexual issues, and plan for rehab even if immediate function can’t be restored; and (2) provide robust psychosocial support – ensure the patient and partner have counseling, encourage open communication, and incorporate mind-body techniques or appropriate complementary therapies to improve well-being. By doing so, we help men maintain a sense of identity and hope through the gruelling treatment process. The knowledge that fertility preservation was done (if applicable) provides comfort regarding the future, and knowing that sexual side effects are being addressed can reduce distress. Men should be reminded that many of these sexual changes are not permanent – for example, “Your testosterone and libido may come back after chemo; this erectile issue might improve once treatment is over and you recover.” Reinforcing the temporary nature (when true) helps patients and partners hang on during this challenging time.

After Treatment: Navigating Survivorship and Recovery

Completing cancer treatment is a momentous milestone, but it often marks the beginning of a new phase of challenges. As men enter survivorship, attention turns to long-term recovery of fertility and sexual function and how to fulfill life plans that may have been on hold. The post-treatment stage is characterized by questions like: “Will my fertility return or do I need to use the sperm I banked?”; “What are my options if I am infertile now?”; “How can I improve my erections or sex life after all these treatments?”; and importantly, “How do I cope emotionally with any lasting changes?” This phase can be complex – some issues may resolve on their own over time, while others require active interventions. The role of specialist care (reproductive urology, endocrinology, sexual medicine, fertility clinics) is perhaps most crucial in this stage, to evaluate the damage and implement solutions for rehabilitation.

Fertility Outcomes and Family-Building After Cancer

The impact of cancer treatment on a man’s fertility can be assessed after a suitable waiting period once therapy ends. Generally, oncologists advise men to wait about 6 to 12 months after completion of chemotherapy or radiation before attempting to conceive naturally. This allows time for new sperm production that was not exposed to chemotherapy, thereby reducing the risk of genetic damage in sperm. Sperm production (spermatogenesis) takes around 3 months for a full cycle, so by 6–12 months post-treatment, any sperm in the ejaculate originated after treatment. At this point, a semen analysis can be performed to see where things stand. If the semen analysis shows sufficient sperm count and motility, the couple might try natural conception. If it shows very low counts or no sperm, further evaluation is needed.

It’s encouraging that a significant proportion of male survivors do eventually have sperm return, especially after treatments that are not uniformly sterilizing. For example, in men treated for testicular cancer with standard chemotherapy, studies have shown that many will see some recovery of sperm counts by 2–5 years post-treatment, though often lower than baseline. One survey of cancer survivors who had banked sperm (mostly testicular cancer patients) found that about 50% of those who attempted conception after treatment were able to achieve a natural pregnancy with their partner. Specifically, among those survivors, 68% achieved pregnancy naturally without needing their banked samples. This suggests that more than half regained enough fertility to conceive on their own. For those who did not succeed naturally, assisted reproduction using banked sperm was a viable path: in that same study, 11 men ended up using their cryopreserved sperm, and nearly half of those (45%) achieved pregnancy with those samples. These outcomes highlight two things: many survivors can conceive naturally, and having banked sperm provides a valuable backup for those who cannot.

Of course, outcomes vary by cancer type and treatment: survivors of Hodgkin lymphoma who received high-dose alkylating chemo often have a higher rate of permanent infertility compared to, say, survivors of testicular cancer who got cisplatin-based chemo where partial recovery is more common. Radiation to both testes (like total body irradiation for bone marrow transplant) or high doses near them can cause permanent damage as well. In cases where the patient had a surgical removal of both testes (bilateral orchiectomy, which is rare except maybe sequential cancers or certain hormone-driven cancers), he will be infertile (no sperm source) and also require lifelong testosterone replacement. Similarly, a man who underwent radical prostatectomy for prostate cancer will produce sperm in the testes, but because the pathway for semen (prostate and seminal vesicles) is removed, he will have a dry ejaculation (no fluid coming out). This results in infertility even if sperm are made (they can’t reach the outside naturally). Such patients would need sperm retrieval from the testicles and in vitro fertilization techniques to have a child, since intercourse cannot deliver sperm (we call this obstructive azoospermia, because the tract is surgically obstructed). Men who had retroperitoneal lymph node dissection (RPLND) for testicular cancer might experience retrograde ejaculation due to nerve damage – sperm go into the bladder rather than out through the penis. This also causes infertility unless assisted, but sometimes medications (like pseudoephedrine) can improve antegrade ejaculation or sperm can be harvested from urine.

Given these complexities, an individualized approach is necessary. A male fertility specialist (reproductive urologist, also known as an Andrologist) will typically do a thorough assessment after treatment: semen analyses (often multiple, since counts can fluctuate), hormone tests (testosterone, FSH, etc.), and a physical exam. If the patient did not bank sperm and now has azoospermia (no sperm), the specialist might discuss options like surgical sperm retrieval. In some cases of chemo-induced azoospermia, there may be isolated pockets of sperm production in the testis that a procedure like micro-TESE (microsurgical testicular sperm extraction) could find. If sperm are found, they can be used with IVF/ICSI (in vitro fertilization with intracytoplasmic sperm injection) to attempt a pregnancy. This is a complex process, but it’s an option for those determined to have a biological child. If no sperm can be found (or if the patient elects so), donor sperm is an alternative to consider, as is adoption. These options carry emotional weight, and counseling is important to help the patient (and partner) explore feelings around using donor gametes or adopting. Many men initially feel resistance to the idea of donor sperm (for some it challenges their sense of lineage or masculinity), but others become more open to it over time, especially if having a family is a strong desire. Professional counseling and hearing from other families who used donor conception can help in this decision-making.

For men who did bank sperm, the post-treatment stage is when those vials might be called upon. Fertility clinics can thaw samples and use them for insemination or IVF. The choice often depends on the quality and number of sperm stored. If a man has a decent count frozen, intrauterine insemination (IUI) might be attempted (where the sperm is processed and placed into the partner’s uterus at ovulation). If the frozen sample is very limited or of poor motility, IVF with ICSI is usually preferred, because ICSI can achieve fertilization with even a single viable sperm injected into an egg. Many healthy babies have been born from sperm frozen for years or even decades. Notably, long-term cryostorage does not seem to harm sperm; there are reports of successful pregnancies from sperm stored over 20 years. So men should be reassured that as long as the sample was initially of usable quality, it remains a viable resource essentially indefinitely.

A common patient question at this stage is: “Will my kids be healthy if they’re conceived after I had cancer?” The reassuring answer from research is yes – children of cancer survivors generally do not have higher rates of birth defects or genetic problems compared to the general population, provided conception happens after treatment (and not during exposure). Large studies, including those of childhood cancer survivors who later had children, found no increase in birth defects among offspring of male survivors who had chemo or radiation in the past. The Vanderbilt University study highlighted in the news showed survivors’ children had no higher risk of congenital anomalies than those of people without a cancer history. This is likely because while chemo can damage some sperm DNA at the time, men produce new sperm once treatment is over, and the sperm that manage to fertilize an egg are typically those with intact DNA (severely damaged ones likely can’t succeed in fertilization or result in viable pregnancy). However, if a man banked sperm before treatment, one might wonder if the cancer or pre-treatment condition could affect that sperm. There’s no evidence that cancer itself (aside from genetic hereditary syndromes) causes mutations in sperm that lead to birth defects. Sperm banking is considered safe and effective; children born from frozen-thawed sperm of cancer patients have not shown higher rates of abnormalities attributable to the father’s cancer. So patients can be reassured on this front. That said, for peace of mind, some couples choose to undergo genetic counseling when planning pregnancy after cancer, especially if the cancer had any hereditary component. For instance, if a young man had bilateral testicular cancer or a known cancer predisposition syndrome, a genetic counselor might discuss any risks to children. But in general, cancer survivors can have healthy, biologically related children.

Beyond biology, there’s the emotional facet of family-building after cancer. Some men experience a sense of urgency to “make up for lost time,” especially if they had to delay having kids until after survival was assured. Others may have a lingering fear of recurrence and worry about bringing a child into the world in case the cancer comes back. These are valid concerns that should be addressed empathetically. Survivorship programs often include counseling on parenting after cancer, and connecting with other survivor parents can be helpful. Involving the partner in these discussions is essential, as family decisions are joint ones.

Rehabilitation of Sexual Function and Intimacy

After completing treatment, sexual function in men can either improve (as temporary side effects wear off) or, in some cases, worsen before stabilizing (some treatment effects are delayed). For example, a man who finished chemotherapy might find his energy and libido gradually returning within a few months as his body recovers. If he had temporary ED due to fatigue or low blood counts, that might get better on its own. However, men who had surgery or radiation may find that they need assistance to regain satisfactory sexual function.

The first step is a frank evaluation: Are there physiological issues like ED, low testosterone, or loss of sensation? Erectile Dysfunction: If ED is present, its severity and cause (arteriogenic vs. neurogenic vs. psychogenic) should be considered. As mentioned earlier, many prostate cancer survivors have long-term ED. In these cases, the urologist or sexual medicine specialist will likely start with PDE5 inhibitors if not contraindicated. These medications (sildenafil, tadalafil, etc.) help increase blood flow to the penis. In men who have partial erections but not enough for intercourse, these drugs can significantly improve rigidity. They work best if the nerve pathways are at least partially intact. For those with more severe ED (like non-nerve-sparing prostatectomy patients where nerves were cut), PDE5 inhibitors may not be sufficient. Then second-line therapies come into play: vacuum erection devices (VEDs), which use suction to draw blood into the penis, can produce an erection that is maintained with a constriction ring at the base. VEDs do not rely on nerves or blood vessel function, so they can work in almost any scenario, though some find them cumbersome or report the erection feels “cold” or unnatural. Another option is intracavernosal injection therapy: the man self-injects a small needle into the penile shaft to deliver a vasodilator (like alprostadil or a combination called Trimix). This directly induces an erection typically within 5–15 minutes that can last about 30–60 minutes. It’s highly effective even in men with nerve damage, since it acts pharmacologically on the muscle. The downsides are the need for an injection each time and potential side effects like pain or priapism (prolonged erection). Many couples find it a good solution if they can get over the initial intimidation of the needle; it often restores a reliable ability to have intercourse. Lastly, for men with severe, permanent ED who don’t respond or don’t tolerate other treatments, a penile implant (prosthesis) is an excellent surgical option. A penile implant is a device surgically placed in the penis (usually an inflatable prosthesis with pumps in the scrotum) that can produce an erection on demand. Patient satisfaction rates with implants are very high (often >85-90% for both patient and partner) because it provides spontaneity and reliable rigidity. Typically, implants are considered once a patient is clearly not going to recover natural erections and simpler methods either fail or are unsatisfactory. For a younger man, doctors might have him try less invasive methods for a year or two post-treatment before opting for an implant, but this can be individualized based on how much the ED affects his quality of life.

Orgasm and Ejaculation issues: Some survivors have changes in orgasm even if they regain erectile function. Men post-prostatectomy, for example, will experience dry orgasms (no ejaculate). They often describe the sensation as different – sometimes a bit shorter or less intense – but many still find it pleasurable once they adapt to the new normal. They should be counseled about this beforehand, so it’s not alarming. There is no treatment to bring back the fluid, since the glands producing semen have been removed. But on the positive side, not ejaculating means no mess and some couples find that advantageous. For those with retrograde ejaculation (e.g., after RPLND surgery or due to diabetes or certain medications), sometimes taking pseudoephedrine or imipramine before sex can improve antegrade ejaculation by tightening the bladder neck. If fertility is desired, sperm can often be retrieved from the urine after orgasm (separating it in a lab) for use in assisted reproduction.

Low testosterone (hypogonadism): Some men emerge from treatment with suboptimal testosterone levels – this could be due to chemo effect on testes, surgical loss of testes, or simply age and stress. Symptoms of low T include fatigue, low libido, depressed mood, and difficulty with erections. If the patient’s cancer is not contraindicated (for example, it’s not prostate cancer or another cancer worsened by testosterone), then testosterone replacement therapy (TRT) might be considered to improve overall well-being and sexual function. In a man who had testicular cancer and now has a borderline testosterone, giving TRT can restore normal energy and sex drive, but caution: exogenous TRT will shut down any remaining sperm production in the testes (because it suppresses FSH/LH). So if fertility is still desired and he’s hoping for natural conception, TRT is not ideal. Instead, alternatives like clomiphene citrate, an aromatase inhibitor, or hCG injection can sometimes be used to stimulate the body’s own testosterone production while also supporting sperm production. These are off-label uses but commonly done in the field of fertility for men with low T who still want kids. Each case must be tailored: for a man who is done with childbearing and primarily wants sexual function back, TRT (gel, injections, or pellets) could be a straightforward solution. For a younger man wanting to father children, a fertility specialist might try a regime of hCG (which acts like LH) to stimulate testosterone and sperm output, and add FSH injections if needed to spur sperm production, in attempt to “jump start” fertility after chemo. There have been cases of men with post-chemo azoospermia who recovered sperm in ejaculate after months of such stimulation, though it’s not guaranteed.

Psychological and relational aspects: After treatment, once the focus shifts from survival to living life, many men process the trauma of what they’ve been through. Sexual intimacy can sometimes be initially daunting. If there were months of not being sexually active, resuming intercourse may bring performance anxiety. The man might worry about whether his body will respond, or he may have internalized some of the stress. Performance anxiety can lead to a cycle of erectile difficulty even if the physical cause is addressed. This is where sexual counseling can be very effective. Techniques from sex therapy, such as sensate focus exercises (which have the couple engage in intimate touch without the goal of intercourse or orgasm at first), can gradually rebuild sexual confidence. As indicated earlier, mindfulness-based sex therapy has shown promise: by focusing on present sensations and reducing the emphasis on “achievement” (like sustaining an erection or giving the partner an orgasm), men often feel less pressure and gradually their natural arousal improves. A 2023 randomized trial even found that group mindfulness therapy was beneficial for couples dealing with sexual dysfunction after prostate cancer. Men who develop a conditioned fear of failure (sometimes termed psychogenic ED) can unlearn it with the help of therapy and sometimes a low-dose medication to boost confidence.

It’s also crucial to involve partners in the sexual rehabilitation process. Both parties may have fears or misconceptions. For example, a wife might fear resuming sex will hurt her husband if he’s had recent surgery, or a partner might not understand why the patient seems disinterested and take it personally. Joint counseling sessions or couples’ exercises can improve understanding. Partners of male survivors have their own journey – some female partners experience anxiety about initiating sex, worrying it might not succeed and thus hurt the man’s self-esteem. Honest, empathetic communication needs to be fostered: both need to express their needs and also their willingness to be patient and work together. Many couples report that overcoming cancer strengthened their relationship in non-physical ways, and now they must renegotiate their physical relationship as a team rather than see it as a performance issue of one person.

Complementary approaches in survivorship can complement medical treatments. For example, some survivors explore herbal supplements reputed to enhance male fertility or sexual function. Supplements like ginseng, L-arginine, maca root, Tongkat Ali, or tribulus are marketed for boosting libido or erection quality. Scientific evidence for these is varied and often not specific to cancer survivors. Panax ginseng (Korean red ginseng) has some studies suggesting improved erectile function in men with ED, possibly via nitric oxide pathways, but quality control and dosing are issues with over-the-counter herbs. L-arginine is an amino acid that can act as a nitric oxide donor and at high doses might help mild ED, but results are inconsistent. While such supplements may have some benefit for idiopathic ED, in the context of nerve damage or severe vasculogenic ED like after pelvic surgery, their effects are likely modest at best. Patients should be advised to use reputable brands if they choose supplements and to be cautious of “male enhancement” products that sometimes contain undeclared prescription drug ingredients.

For fertility, some survivors take antioxidant combinations post-treatment to attempt to improve sperm quality – these might include vitamin E, vitamin C, coenzyme Q10, zinc, selenium, L-carnitine, etc. A Cochrane review of antioxidants in subfertile men (not specific to cancer survivors) found some evidence of increased pregnancy rates with antioxidant use, though the trials were heterogeneous. In practice, a fertility specialist might recommend a daily antioxidant male prenatal vitamin for a man trying to conceive after cancer, reasoning that it could help neutralize oxidative stress in remaining sperm-producing cells. It’s relatively low-risk, though definitive proof in cancer survivors is not there. On the cutting edge, there are experimental therapies like using the survivor’s own testicular stem cells or germ cell transplantation being researched to restore fertility, but those are not yet in clinical use.

Partner and family planning in survivorship can also have social implications. For example, if a man is now infertile and the couple decides to use donor sperm, extended family reactions can be a worry (though donor conception is common and usually accepted once understood). Or if they choose adoption, navigating that process post-cancer can be challenging (some adoption agencies have requirements about cancer remission period). Guidance from social workers or advocacy organizations can be valuable here.

Throughout survivorship, one thing men consistently report is that having their concerns validated by healthcare providers makes a big difference. Many cancer follow-up clinics historically focused on recurrence monitoring and general health, often overlooking sexual and fertility issues. Increasingly, survivorship clinics are incorporating dedicated time for these topics or having specialists in male sexual health as part of the team. For instance, a survivorship program may offer a “Men’s health after cancer” seminar or a clinic run by a urologist to address erectile dysfunction and low testosterone in survivors. The medical community has recognized that sexuality is a legitimate quality-of-life domain for survivors. In fact, one survey highlighted that while nearly 90% of survivors had sexual health issues, less than 30% had been asked by their doctors, yet the majority wanted a standard way to discuss it. Many respondents favored the idea of a standard questionnaire to prompt discussion, suggesting patients actually welcome their providers bringing it up. Therefore, in the post-treatment visits, providers should routinely ask, “How is your sexual function? Any issues with intimacy or any concerns about fertility now that you’ve finished treatment?” This opens the door. If the provider isn’t knowledgeable, a referral should be made. Patients should not be left to suffer in silence or think “maybe nothing can be done.” As we’ve outlined, there are many interventions available, from medical to surgical to psychological, that can significantly improve a man’s sexual health after cancer.

Partner, Family, and Social Influence Across All Stages

While we have touched on partner and family roles at each stage, it’s worth summarizing their influence throughout the cancer journey, as it often evolves:

• Before Treatment: Partners/family help in decision-making (e.g., urging the patient to bank sperm, offering hope for future family). They provide emotional grounding. Potential negative influence could be if they discourage talking about fertility (“just focus on survival, we’ll worry about kids later”) which might lead to missed opportunities. Health providers should, when appropriate, educate the family that addressing fertility is part of focusing on survivorship and not a distraction.
• During Treatment: Partners frequently become caregivers. A positive influence includes providing love, patience, and physical care, which can strengthen emotional intimacy. Some couples report a deeper bond formed during adversity. However, the stress can also reveal cracks if communication is poor. A partner’s frustration or burnout can unintentionally manifest as withdrawal or conflict. Similarly, family members might hover or be overprotective, which could make the man feel infantilized or emasculated. It’s important to balance support with respect for the patient’s autonomy. Support groups for caregivers can be helpful so that partners/family manage their own stress and don’t inadvertently project it onto the patient.
• After Treatment: Partners and family often celebrate the end of cancer therapy, but may not anticipate the ongoing struggles with fertility and sexual health. A partner’s positive role here is as a collaborator in finding solutions – e.g., accompanying the man to doctor visits about ED or fertility, or being willing to explore alternative family-building methods together. Negative influences might come from family pressure (“When will you give us a baby?”) especially if they are unaware of the fertility challenges. This can cause the survivor distress. It might be wise for survivors to inform close family about their situation in a controlled manner, to temper expectations. For instance, some survivors choose to tell their parents, “The treatment affected my fertility, and we are exploring options. We’ll let you know when we have news, but please understand it may take time or we may choose other paths like donor or adoption.” Educating family can generate understanding and even support rather than pressure.

One cannot overstate that a supportive partner can dramatically improve a man’s adaptation to life after cancer. Studies have shown that cancer survivors with strong partner communication report better sexual satisfaction even if function isn’t fully restored. On the flip side, single survivors or those whose relationships did not endure face the additional challenge of dating with these new issues. Dating anxiety for a survivor might include “When do I tell a new partner about my fertility or sexual limitations?” For these individuals, counseling and perhaps connecting with survivor dating forums can provide strategies and confidence. Many survivors find that the right partner will accept them fully, and honesty (at an appropriate time once mutual trust is established) is the best approach.

Specialist Approaches at Each Stage: Summary Table

To synthesize how a specialist (such as a reproductive urologist or oncofertility expert) might tailor interventions at each phase, the following table highlights key approaches:

(Table: Key specialist interventions for fertility, sexual function, and psychosocial support at each stage of the cancer journey.)

Conclusion

Fertility and sexual health are central quality-of-life issues for male cancer patients, and addressing them requires a proactive, empathetic approach from the time of diagnosis through survivorship. For medical professionals, especially oncologists, urologists, and allied providers, it is essential to initiate conversations about these “uncomfortable” topics – doing so legitimizes the patient’s concerns and opens the door to intervention. At diagnosis, providing information and fertility preservation options empowers men and offers hope that life after cancer can include fatherhood. During treatment, managing side effects and maintaining some degree of intimacy or sexual activity (even in modified forms) can preserve a man’s sense of normalcy and reduce long-term complications. After treatment, a combination of medical therapies (from hormone treatment to advanced reproductive technologies and sexual rehabilitation techniques) and psychosocial support can help survivors reclaim their fertility potential or find alternate paths to parenthood, as well as restore satisfying sexual relationships.

Partners, family, and friends play a pivotal supportive role at each step – their understanding and encouragement often bolster the patient’s own coping ability. As such, involving them when appropriate and providing education to the support network is beneficial. Where partners or family exert negative pressure or discomfort (often out of ignorance or fear), professional counseling can often realign everyone toward the common goal of the patient’s well-being.

From an interdisciplinary perspective, this domain of oncofertility and sexual rehabilitation exemplifies the need for collaboration: oncologists, reproductive specialists, sexual medicine experts, psychologists, and patient navigators must work together. Encouragingly, awareness has grown in recent years. Guidelines from ASCO and others firmly state that fertility preservation is a standard part of oncology care, and survivorship care plans increasingly include sexual health assessments. But gaps remain – studies show many patients still are not counseled or referred in time. By continuing to conduct research, share success stories, and train healthcare providers in how to address male reproductive and sexual matters, we can improve the landscape.

For the patient reading this, the key message is: you are not alone, and these issues are not trivial. There are solutions and specialists dedicated to helping you. Do not hesitate to bring up fertility or sexual concerns with your care team – if your doctor doesn’t have answers, ask for a referral to someone who does. For the healthcare provider, the key message is: don’t shy away from these topics. A simple question like, “Have you thought about whether you might want children in the future?” or “How has your sex life been since starting treatment?” can be life-changing. It can lead to interventions that prevent heartbreak or restore a sense of wholeness to a man who has already been through so much. As one survivor put it, addressing these concerns “allowed me to feel like myself again, not just a cancer patient.” In modern cancer care, success is no longer measured only in years of survival, but also in the quality of survival – helping men lead fulfilling lives that include the possibility of raising a family and enjoying intimacy is a crucial part of that mission.

References:

1. Su HI, Lacchetti C, Letourneau J, et al. Fertility Preservation in People With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2025;43(12):1488-1515.
2. Yumura Y, Takeshima T, Komeya M, et al. Long-Term Fertility Function Sequelae in Young Male Cancer Survivors. World J Mens Health. 2023;41(2):255-271.
3. Kimelman D, Torrens A, Bonelli C, Sapiro R. Fertility preservation in male cancer patients: Counseling and reproductive outcomes (Uruguay cohort). Front Cell Dev Biol. 2023;11:1240152.
4. Pacey A, Merrick H, Arden-Close E, et al. Implications of sperm banking for quality of life up to 1 year after cancer diagnosis. Br J Cancer. 2013;108(5):1004-1011.
5. Hu Y, Fu X, Jiang X, et al. The experience of fertility concerns in patients with testicular cancer: a qualitative study. Support Care Cancer. 2024;32:529.
6. Madan R, Dracham CB, Khosla D, Goyal S, Yadav AK. Erectile dysfunction and cancer: current perspective. Radiat Oncol J. 2020;38(4):217-225.
7. Nelson R. Cancer therapy affects sexual health in most patients (ASTRO survey results). MDedge Hematology & Oncology News. January 4, 2023.
8. Lopategui DM, Ramasamy R, Aballa TC, et al. Effect of a formal oncofertility program on fertility preservation rates—first year experience. Transl Androl Urol. 2019;8(Suppl 3):S305-S310.
9. Martins RVL, Silva AMS, Duarte AP, Socorro S, Correia S, Maia CJ. Natural Products as Protective Agents for Male Fertility. BioChem. 2021;1(3):122-147.
10. Bossio JA, Miller F, O’Loughlin JI, Brotto LA. Sexual Health Recovery for Prostate Cancer Survivors: The Proposed Role of Acceptance and Mindfulness-Based Interventions. Sex Med Rev. 2019;7(4):627-635.
11. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod.2003;18(1):117-121. 
12. Quinn GP, et al. Patient and physician perspectives on fertility preservation in young men with cancer. J Adolesc Young Adult Oncol. 2011;1(2):72-77.